Chronic Urticaria and Sexual Dysfunction Causes Impact and Treatment

By Stayinghealthy !
Chronic Urticaria and Sexual Dysfunction: A Comprehensive Overview

Chronic urticaria symptoms like hives and itching are closely linked to sexual dysfunction, but treatments such as omalizumab can improve both skin and intimacy
Chronic urticaria not only causes hives—it can also impact intimacy and sexual health / Freepik 

 Chronic urticaria is more than just annoying hives—it can deeply affect a person’s life, including intimacy and sexual well-being. Recent studies uncover the hidden challenges patients face in their sexual health, and how effective treatments may bring relief back where it matters most.


Chronic urticaria (CU), characterized by persistent hives or angioedema lasting six weeks or more, impacts not only physical comfort but also emotional and psychological well-being. A growing body of research reveals that CU can significantly impair sexual health—for both women and men—and that worsening CU symptoms often coincide with greater sexual dysfunction, anxiety, and depression. Encouragingly, treatments like omalizumab show promise in improving sexual function alongside skin symptoms.

1. Prevalence of Sexual Dysfunction in CU Patients

A recent systematic review of 14 studies involving over 1,000 patients with chronic urticaria found that rates of sexual dysfunction were remarkably high—ranging from approximately 54% to 71% in women and 31% to 64% in men. More severe CU symptoms correlated with greater sexual impairment, and associations were also observed with diminished body image, poor sleep quality, and heightened psychological distress. Experts recommend that dermatologists address sexual health when managing CU. Treatments aiming to control CU symptoms—such as omalizumab—may offer meaningful improvements in sexual function.


2. Impact Across Genders and CU Subtypes

In a study of 100 CU patients (both spontaneous and inducible forms) compared to healthy controls, chronic urticaria patients exhibited significantly worse sexual function. Erectile dysfunction affected 43–50% of these men (versus 10% of controls), while female sexual dysfunction reached 70–83% (versus 20% of controls). Lower sexual function scores strongly correlated with poor quality of life, depressive symptoms, and longer disease duration—highlighting the interplay between physical, psychological, and sexual wellbeing.


3. Why CU Harms Sexual Health

Several interconnected factors contribute to sexual dysfunction in chronic urticaria:

  • CU Severity: Higher disease activity—measured by Urticaria Activity Score and poor control—aligns with greater sexual dysfunction.
  • Psychological Burden: Anxiety, depression, and fatigue are prevalent among CU patients and intensify sexual difficulties.
  • Body Image: Visible hives and discomfort can erode self-confidence and intimacy.
  • Sleep Disruption: Pruritus-related sleep loss exacerbates mental fatigue and reduces sexual satisfaction.

Together, these factors form a complex web that undermines sexual quality of life in CU sufferers.


4. Omalizumab: Treating CU and Improving Sexual Function

Omalizumab—an anti-IgE monoclonal antibody used when antihistamines fall short—has become a cornerstone in managing chronic spontaneous urticaria. It effectively reduces hives, itchiness, and improves overall quality of life.

Importantly, real-world data and clinical observations show that omalizumab also enhances sexual function. In a retrospective study, both male and female patients experienced higher sexual function scores after treatment, along with improved depression and quality-of-life indicators.

Moreover, the systematic review reported that, at 12 and 24 weeks post-omalizumab initiation, patients showed significant reductions in CU activity and depression, paired with better sexual function outcomes—affirming the therapy’s dual benefit.


5. Clinical Implications and Recommendations

Given the prevalence and impact of sexual dysfunction in CU, clinicians should:

  • Incorporate sexual health assessments into routine CU care.
  • Use validated measures such as FSFI (Female Sexual Function Index) and IIEF (International Index of Erectile Function) to evaluate sexual function before and during treatment.
  • Recognize that effective CU control—notably with treatments like omalizumab—may significantly improve intimate wellbeing.
  • Adopt a holistic, multidisciplinary approach that addresses physical symptoms, mental health, sleep quality, and self-esteem.

6. Future Directions

While initial findings are promising, further research is needed to:

  • Conduct larger, prospective clinical trials evaluating sexual function outcomes in CU patients on omalizumab or other therapies.
  • Explore if improvements in sexual function vary across CU types (e.g., spontaneous vs. inducible), genders, or treatment protocols.
  • Investigate psychological and behavioral interventions alongside medical therapy to maximize sexual rehabilitation in CU patients.

FAQ

Q: How common is sexual dysfunction in chronic urticaria?
A: Very common—over 50% of women and up to 60% of men with CU report sexual dysfunction, versus much lower rates in healthy individuals.
Q: Why does chronic urticaria affect sexual health?
A: Because active symptoms exacerbate psychological distress, poor sleep, negative body image, and overall lowered quality of life—all of which impair sexual function.
Q: Can CU treatments help with sexual dysfunction?
A: Yes—particularly omalizumab, which both improves skin symptoms and has been shown to enhance sexual function scores in patients treated for CU.
Q: Should healthcare providers ask patients about sexual health?
A: Absolutely—sexual wellbeing is a key part of quality of life and should be addressed alongside physical and psychological care in chronic urticaria management.

Further Reading & References